Lung Cancer

Prevention, Management, and Emerging Therapies

  • David J.¬†Stewart

Part of the Current Clinical Oncology book series (CCO)

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Alejandro Corvalan, Ignacio I. Wistuba
    Pages 1-25
  3. Tonya C. Walser, Jane Yanagawa, Edward Garon, Jay M. Lee, Steven M. Dubinett
    Pages 27-69
  4. Carol J. Etzel, Sumesh Kachroo
    Pages 71-85
  5. Xifeng Wu, Jian Gu
    Pages 87-106
  6. Nir Peled, Robert L. Keith, Fred R. Hirsch
    Pages 107-138
  7. Katherine Pisters
    Pages 139-159
  8. James D. Cox, David J. Stewart
    Pages 161-175
  9. William N. William Jr., David J. Stewart
    Pages 177-194
  10. Leora Horn, Alan Sandler
    Pages 227-252
  11. Benjamin Besse, Jean-Charles Soria
    Pages 253-278
  12. John Nemunaitis, Jack Roth
    Pages 279-303
  13. John Nemunaitis, Jack Roth
    Pages 305-330
  14. David J. Stewart
    Pages 331-393
  15. Emer O. Hanrahan, Bonnie Glisson
    Pages 395-434
  16. Mary Frances McAleer, Reza J. Mehran, Anne Tsao
    Pages 435-465
  17. David Hui, Eduardo Bruera
    Pages 483-502
  18. Sophie Sun, Joan H. Schiller, Monica Spinola, John D. Minna
    Pages 503-514
  19. Back Matter
    Pages 515-538

About this book


This comprehensive resource provides authoritative knowledge of the most up-to-date prevention and treatment strategies for thoracic malignancies. Established and investigational therapies are placed in the context of tumor biology for a full understanding of the pharmacogenetics, etiology, and changing epidemiology of lung cancer. Expert clinicians detail the function of predictive and prognostic factors in the utilization of chemo-radiotherapy, adjuvant and neoadjuvant treatment, and targeted agents. The promises and potential pitfalls of investigational strategies are evaluated with exceptional insight and clarity, with unique attention paid to the mechanisms of drug resistance and targets for lung cancer treatment and prevention. Lung Cancer: Prevention, Management, and Emerging Therapies engages the entire spectrum of therapeutic modalities with focus on systemic approaches. Disease coverage includes newly diagnosed and recurrent non-small cell lung cancer, small cell carcinoma, and mesothelioma. Critical examination of the impact, methodology, and design of clinical trials is presented along with new paradigms for personalized approaches and individual risk assessment.


Antiangiogenesis Cancer Carcinom Clinical trials Lung Malignancy Mesothelioma Non-small cell lung cancer (NSCLC) Novel Agents Prevention Small cell lung cancer (SCLC) Tho Thymoma cancer prevention

Editors and affiliations

  • David J.¬†Stewart
    • 1
  1. 1.M. D. Anderson Cancer CenterUniversity of TexasHoustonU.S.A.

Bibliographic information